

Global Primary Hyperoxaluria Treatment Market Growth 2023-2029

<https://marketpublishers.com/r/G4CD728FDCB0EN.html>

Date: February 2023

Pages: 96

Price: US\$ 3,660.00 (Single User License)

ID: G4CD728FDCB0EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Primary Hyperoxaluria (PH) is a rare genetic disorder caused by deficiencies in glyoxylate metabolism leading to oxalate deposition primarily in kidneys causing end-stage renal disease. It is an inherited autosomal recessive disorder and can be of three types based on the different responsible genes: type 1 (AGXT) (PH-I), type 2 (GRHPR) (PH-II), and type 3 (HOGA1) (PH-III). Signs and symptoms may include recurrent kidney stones, hematuria, and urinary tract infections (UTIs).

LPI (LP Information)' newest research report, the "Primary Hyperoxaluria Treatment Industry Forecast" looks at past sales and reviews total world Primary Hyperoxaluria Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Primary Hyperoxaluria Treatment sales for 2023 through 2029. With Primary Hyperoxaluria Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Primary Hyperoxaluria Treatment industry.

This Insight Report provides a comprehensive analysis of the global Primary Hyperoxaluria Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Primary Hyperoxaluria Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Primary Hyperoxaluria Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors

shaping the global outlook for Primary Hyperoxaluria Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Primary Hyperoxaluria Treatment.

The global Primary Hyperoxaluria Treatment market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Primary Hyperoxaluria Treatment is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Primary Hyperoxaluria Treatment is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Primary Hyperoxaluria Treatment is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Primary Hyperoxaluria Treatment players cover Oxthera, Dicerna Pharmaceuticals, Allena Pharmaceuticals, Biocodex, Alnylam Pharmaceuticals, Tecoland Corporation, Zhejiang Tianxin Pharmaceutical, Takeda Pharmaceuticals and Wuxi Further Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Primary Hyperoxaluria Treatment market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Oral

Intravenous

Others

Segmentation by application

Type 1

Type 2

Type 3

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Oxthera

Dicerna Pharmaceuticals

Allena Pharmaceuticals

Biocodex

Alnylam Pharmaceuticals

Tecoland Corporation

Zhejiang Tianxin Pharmaceutical

Takeda Pharmaceuticals

Wuxi Further Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Primary Hyperoxaluria Treatment market?

What factors are driving Primary Hyperoxaluria Treatment market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Primary Hyperoxaluria Treatment market opportunities vary by end market size?

How does Primary Hyperoxaluria Treatment break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Primary Hyperoxaluria Treatment Annual Sales 2018-2029
 - 2.1.2 World Current & Future Analysis for Primary Hyperoxaluria Treatment by Geographic Region, 2018, 2022 & 2029
 - 2.1.3 World Current & Future Analysis for Primary Hyperoxaluria Treatment by Country/Region, 2018, 2022 & 2029
- 2.2 Primary Hyperoxaluria Treatment Segment by Type
 - 2.2.1 Oral
 - 2.2.2 Intravenous
 - 2.2.3 Others
- 2.3 Primary Hyperoxaluria Treatment Sales by Type
 - 2.3.1 Global Primary Hyperoxaluria Treatment Sales Market Share by Type (2018-2023)
 - 2.3.2 Global Primary Hyperoxaluria Treatment Revenue and Market Share by Type (2018-2023)
 - 2.3.3 Global Primary Hyperoxaluria Treatment Sale Price by Type (2018-2023)
- 2.4 Primary Hyperoxaluria Treatment Segment by Application
 - 2.4.1 Type
 - 2.4.2 Type
 - 2.4.3 Type
- 2.5 Primary Hyperoxaluria Treatment Sales by Application
 - 2.5.1 Global Primary Hyperoxaluria Treatment Sale Market Share by Application (2018-2023)
 - 2.5.2 Global Primary Hyperoxaluria Treatment Revenue and Market Share by

Application (2018-2023)

2.5.3 Global Primary Hyperoxaluria Treatment Sale Price by Application (2018-2023)

3 GLOBAL PRIMARY HYPEROXALURIA TREATMENT BY COMPANY

3.1 Global Primary Hyperoxaluria Treatment Breakdown Data by Company

3.1.1 Global Primary Hyperoxaluria Treatment Annual Sales by Company (2018-2023)

3.1.2 Global Primary Hyperoxaluria Treatment Sales Market Share by Company (2018-2023)

3.2 Global Primary Hyperoxaluria Treatment Annual Revenue by Company (2018-2023)

3.2.1 Global Primary Hyperoxaluria Treatment Revenue by Company (2018-2023)

3.2.2 Global Primary Hyperoxaluria Treatment Revenue Market Share by Company (2018-2023)

3.3 Global Primary Hyperoxaluria Treatment Sale Price by Company

3.4 Key Manufacturers Primary Hyperoxaluria Treatment Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Primary Hyperoxaluria Treatment Product Location Distribution

3.4.2 Players Primary Hyperoxaluria Treatment Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR PRIMARY HYPEROXALURIA TREATMENT BY GEOGRAPHIC REGION

4.1 World Historic Primary Hyperoxaluria Treatment Market Size by Geographic Region (2018-2023)

4.1.1 Global Primary Hyperoxaluria Treatment Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Primary Hyperoxaluria Treatment Annual Revenue by Geographic Region (2018-2023)

4.2 World Historic Primary Hyperoxaluria Treatment Market Size by Country/Region (2018-2023)

4.2.1 Global Primary Hyperoxaluria Treatment Annual Sales by Country/Region (2018-2023)

4.2.2 Global Primary Hyperoxaluria Treatment Annual Revenue by Country/Region

(2018-2023)

4.3 Americas Primary Hyperoxaluria Treatment Sales Growth

4.4 APAC Primary Hyperoxaluria Treatment Sales Growth

4.5 Europe Primary Hyperoxaluria Treatment Sales Growth

4.6 Middle East & Africa Primary Hyperoxaluria Treatment Sales Growth

5 AMERICAS

5.1 Americas Primary Hyperoxaluria Treatment Sales by Country

5.1.1 Americas Primary Hyperoxaluria Treatment Sales by Country (2018-2023)

5.1.2 Americas Primary Hyperoxaluria Treatment Revenue by Country (2018-2023)

5.2 Americas Primary Hyperoxaluria Treatment Sales by Type

5.3 Americas Primary Hyperoxaluria Treatment Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Primary Hyperoxaluria Treatment Sales by Region

6.1.1 APAC Primary Hyperoxaluria Treatment Sales by Region (2018-2023)

6.1.2 APAC Primary Hyperoxaluria Treatment Revenue by Region (2018-2023)

6.2 APAC Primary Hyperoxaluria Treatment Sales by Type

6.3 APAC Primary Hyperoxaluria Treatment Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Primary Hyperoxaluria Treatment by Country

7.1.1 Europe Primary Hyperoxaluria Treatment Sales by Country (2018-2023)

7.1.2 Europe Primary Hyperoxaluria Treatment Revenue by Country (2018-2023)

7.2 Europe Primary Hyperoxaluria Treatment Sales by Type

7.3 Europe Primary Hyperoxaluria Treatment Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Primary Hyperoxaluria Treatment by Country

8.1.1 Middle East & Africa Primary Hyperoxaluria Treatment Sales by Country (2018-2023)

8.1.2 Middle East & Africa Primary Hyperoxaluria Treatment Revenue by Country (2018-2023)

8.2 Middle East & Africa Primary Hyperoxaluria Treatment Sales by Type

8.3 Middle East & Africa Primary Hyperoxaluria Treatment Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Primary Hyperoxaluria Treatment

10.3 Manufacturing Process Analysis of Primary Hyperoxaluria Treatment

10.4 Industry Chain Structure of Primary Hyperoxaluria Treatment

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

- 11.1.2 Indirect Channels
- 11.2 Primary Hyperoxaluria Treatment Distributors
- 11.3 Primary Hyperoxaluria Treatment Customer

12 WORLD FORECAST REVIEW FOR PRIMARY HYPEROXALURIA TREATMENT BY GEOGRAPHIC REGION

- 12.1 Global Primary Hyperoxaluria Treatment Market Size Forecast by Region
 - 12.1.1 Global Primary Hyperoxaluria Treatment Forecast by Region (2024-2029)
 - 12.1.2 Global Primary Hyperoxaluria Treatment Annual Revenue Forecast by Region (2024-2029)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Primary Hyperoxaluria Treatment Forecast by Type
- 12.7 Global Primary Hyperoxaluria Treatment Forecast by Application

13 KEY PLAYERS ANALYSIS

- 13.1 Oxthera
 - 13.1.1 Oxthera Company Information
 - 13.1.2 Oxthera Primary Hyperoxaluria Treatment Product Portfolios and Specifications
 - 13.1.3 Oxthera Primary Hyperoxaluria Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.1.4 Oxthera Main Business Overview
 - 13.1.5 Oxthera Latest Developments
- 13.2 Dicerna Pharmaceuticals
 - 13.2.1 Dicerna Pharmaceuticals Company Information
 - 13.2.2 Dicerna Pharmaceuticals Primary Hyperoxaluria Treatment Product Portfolios and Specifications
 - 13.2.3 Dicerna Pharmaceuticals Primary Hyperoxaluria Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.2.4 Dicerna Pharmaceuticals Main Business Overview
 - 13.2.5 Dicerna Pharmaceuticals Latest Developments
- 13.3 Allena Pharmaceuticals
 - 13.3.1 Allena Pharmaceuticals Company Information
 - 13.3.2 Allena Pharmaceuticals Primary Hyperoxaluria Treatment Product Portfolios and Specifications

13.3.3 Allena Pharmaceuticals Primary Hyperoxaluria Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.3.4 Allena Pharmaceuticals Main Business Overview

13.3.5 Allena Pharmaceuticals Latest Developments

13.4 Biocodex

13.4.1 Biocodex Company Information

13.4.2 Biocodex Primary Hyperoxaluria Treatment Product Portfolios and Specifications

13.4.3 Biocodex Primary Hyperoxaluria Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.4.4 Biocodex Main Business Overview

13.4.5 Biocodex Latest Developments

13.5 Alnylam Pharmaceuticals

13.5.1 Alnylam Pharmaceuticals Company Information

13.5.2 Alnylam Pharmaceuticals Primary Hyperoxaluria Treatment Product Portfolios and Specifications

13.5.3 Alnylam Pharmaceuticals Primary Hyperoxaluria Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.5.4 Alnylam Pharmaceuticals Main Business Overview

13.5.5 Alnylam Pharmaceuticals Latest Developments

13.6 Tecoland Corporation

13.6.1 Tecoland Corporation Company Information

13.6.2 Tecoland Corporation Primary Hyperoxaluria Treatment Product Portfolios and Specifications

13.6.3 Tecoland Corporation Primary Hyperoxaluria Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.6.4 Tecoland Corporation Main Business Overview

13.6.5 Tecoland Corporation Latest Developments

13.7 Zhejiang Tianxin Pharmaceutical

13.7.1 Zhejiang Tianxin Pharmaceutical Company Information

13.7.2 Zhejiang Tianxin Pharmaceutical Primary Hyperoxaluria Treatment Product Portfolios and Specifications

13.7.3 Zhejiang Tianxin Pharmaceutical Primary Hyperoxaluria Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.7.4 Zhejiang Tianxin Pharmaceutical Main Business Overview

13.7.5 Zhejiang Tianxin Pharmaceutical Latest Developments

13.8 Takeda Pharmaceuticals

13.8.1 Takeda Pharmaceuticals Company Information

13.8.2 Takeda Pharmaceuticals Primary Hyperoxaluria Treatment Product Portfolios

and Specifications

13.8.3 Takeda Pharmaceuticals Primary Hyperoxaluria Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.8.4 Takeda Pharmaceuticals Main Business Overview

13.8.5 Takeda Pharmaceuticals Latest Developments

13.9 Wuxi Further Pharmaceutical

13.9.1 Wuxi Further Pharmaceutical Company Information

13.9.2 Wuxi Further Pharmaceutical Primary Hyperoxaluria Treatment Product Portfolios and Specifications

13.9.3 Wuxi Further Pharmaceutical Primary Hyperoxaluria Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.9.4 Wuxi Further Pharmaceutical Main Business Overview

13.9.5 Wuxi Further Pharmaceutical Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Primary Hyperoxaluria Treatment Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Table 2. Primary Hyperoxaluria Treatment Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)

Table 3. Major Players of Oral

Table 4. Major Players of Intravenous

Table 5. Major Players of Others

Table 6. Global Primary Hyperoxaluria Treatment Sales by Type (2018-2023) & (K Units)

Table 7. Global Primary Hyperoxaluria Treatment Sales Market Share by Type (2018-2023)

Table 8. Global Primary Hyperoxaluria Treatment Revenue by Type (2018-2023) & (\$ million)

Table 9. Global Primary Hyperoxaluria Treatment Revenue Market Share by Type (2018-2023)

Table 10. Global Primary Hyperoxaluria Treatment Sale Price by Type (2018-2023) & (US\$/Unit)

Table 11. Global Primary Hyperoxaluria Treatment Sales by Application (2018-2023) & (K Units)

Table 12. Global Primary Hyperoxaluria Treatment Sales Market Share by Application (2018-2023)

Table 13. Global Primary Hyperoxaluria Treatment Revenue by Application (2018-2023)

Table 14. Global Primary Hyperoxaluria Treatment Revenue Market Share by Application (2018-2023)

Table 15. Global Primary Hyperoxaluria Treatment Sale Price by Application (2018-2023) & (US\$/Unit)

Table 16. Global Primary Hyperoxaluria Treatment Sales by Company (2018-2023) & (K Units)

Table 17. Global Primary Hyperoxaluria Treatment Sales Market Share by Company (2018-2023)

Table 18. Global Primary Hyperoxaluria Treatment Revenue by Company (2018-2023) (\$ Millions)

Table 19. Global Primary Hyperoxaluria Treatment Revenue Market Share by Company (2018-2023)

Table 20. Global Primary Hyperoxaluria Treatment Sale Price by Company (2018-2023)

& (US\$/Unit)

Table 21. Key Manufacturers Primary Hyperoxaluria Treatment Producing Area Distribution and Sales Area

Table 22. Players Primary Hyperoxaluria Treatment Products Offered

Table 23. Primary Hyperoxaluria Treatment Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

Table 24. New Products and Potential Entrants

Table 25. Mergers & Acquisitions, Expansion

Table 26. Global Primary Hyperoxaluria Treatment Sales by Geographic Region (2018-2023) & (K Units)

Table 27. Global Primary Hyperoxaluria Treatment Sales Market Share Geographic Region (2018-2023)

Table 28. Global Primary Hyperoxaluria Treatment Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 29. Global Primary Hyperoxaluria Treatment Revenue Market Share by Geographic Region (2018-2023)

Table 30. Global Primary Hyperoxaluria Treatment Sales by Country/Region (2018-2023) & (K Units)

Table 31. Global Primary Hyperoxaluria Treatment Sales Market Share by Country/Region (2018-2023)

Table 32. Global Primary Hyperoxaluria Treatment Revenue by Country/Region (2018-2023) & (\$ millions)

Table 33. Global Primary Hyperoxaluria Treatment Revenue Market Share by Country/Region (2018-2023)

Table 34. Americas Primary Hyperoxaluria Treatment Sales by Country (2018-2023) & (K Units)

Table 35. Americas Primary Hyperoxaluria Treatment Sales Market Share by Country (2018-2023)

Table 36. Americas Primary Hyperoxaluria Treatment Revenue by Country (2018-2023) & (\$ Millions)

Table 37. Americas Primary Hyperoxaluria Treatment Revenue Market Share by Country (2018-2023)

Table 38. Americas Primary Hyperoxaluria Treatment Sales by Type (2018-2023) & (K Units)

Table 39. Americas Primary Hyperoxaluria Treatment Sales by Application (2018-2023) & (K Units)

Table 40. APAC Primary Hyperoxaluria Treatment Sales by Region (2018-2023) & (K Units)

Table 41. APAC Primary Hyperoxaluria Treatment Sales Market Share by Region

(2018-2023)

Table 42. APAC Primary Hyperoxaluria Treatment Revenue by Region (2018-2023) & (\$ Millions)

Table 43. APAC Primary Hyperoxaluria Treatment Revenue Market Share by Region (2018-2023)

Table 44. APAC Primary Hyperoxaluria Treatment Sales by Type (2018-2023) & (K Units)

Table 45. APAC Primary Hyperoxaluria Treatment Sales by Application (2018-2023) & (K Units)

Table 46. Europe Primary Hyperoxaluria Treatment Sales by Country (2018-2023) & (K Units)

Table 47. Europe Primary Hyperoxaluria Treatment Sales Market Share by Country (2018-2023)

Table 48. Europe Primary Hyperoxaluria Treatment Revenue by Country (2018-2023) & (\$ Millions)

Table 49. Europe Primary Hyperoxaluria Treatment Revenue Market Share by Country (2018-2023)

Table 50. Europe Primary Hyperoxaluria Treatment Sales by Type (2018-2023) & (K Units)

Table 51. Europe Primary Hyperoxaluria Treatment Sales by Application (2018-2023) & (K Units)

Table 52. Middle East & Africa Primary Hyperoxaluria Treatment Sales by Country (2018-2023) & (K Units)

Table 53. Middle East & Africa Primary Hyperoxaluria Treatment Sales Market Share by Country (2018-2023)

Table 54. Middle East & Africa Primary Hyperoxaluria Treatment Revenue by Country (2018-2023) & (\$ Millions)

Table 55. Middle East & Africa Primary Hyperoxaluria Treatment Revenue Market Share by Country (2018-2023)

Table 56. Middle East & Africa Primary Hyperoxaluria Treatment Sales by Type (2018-2023) & (K Units)

Table 57. Middle East & Africa Primary Hyperoxaluria Treatment Sales by Application (2018-2023) & (K Units)

Table 58. Key Market Drivers & Growth Opportunities of Primary Hyperoxaluria Treatment

Table 59. Key Market Challenges & Risks of Primary Hyperoxaluria Treatment

Table 60. Key Industry Trends of Primary Hyperoxaluria Treatment

Table 61. Primary Hyperoxaluria Treatment Raw Material

Table 62. Key Suppliers of Raw Materials

Table 63. Primary Hyperoxaluria Treatment Distributors List
Table 64. Primary Hyperoxaluria Treatment Customer List
Table 65. Global Primary Hyperoxaluria Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Primary Hyperoxaluria Treatment Revenue Forecast by Region (2024-2029) & (\$ millions)
Table 67. Americas Primary Hyperoxaluria Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Primary Hyperoxaluria Treatment Revenue Forecast by Country (2024-2029) & (\$ millions)
Table 69. APAC Primary Hyperoxaluria Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Primary Hyperoxaluria Treatment Revenue Forecast by Region (2024-2029) & (\$ millions)
Table 71. Europe Primary Hyperoxaluria Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Primary Hyperoxaluria Treatment Revenue Forecast by Country (2024-2029) & (\$ millions)
Table 73. Middle East & Africa Primary Hyperoxaluria Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Primary Hyperoxaluria Treatment Revenue Forecast by Country (2024-2029) & (\$ millions)
Table 75. Global Primary Hyperoxaluria Treatment Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Primary Hyperoxaluria Treatment Revenue Forecast by Type (2024-2029) & (\$ Millions)
Table 77. Global Primary Hyperoxaluria Treatment Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Primary Hyperoxaluria Treatment Revenue Forecast by Application (2024-2029) & (\$ Millions)
Table 79. Oxthera Basic Information, Primary Hyperoxaluria Treatment Manufacturing Base, Sales Area and Its Competitors
Table 80. Oxthera Primary Hyperoxaluria Treatment Product Portfolios and Specifications
Table 81. Oxthera Primary Hyperoxaluria Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
Table 82. Oxthera Main Business
Table 83. Oxthera Latest Developments
Table 84. Dicerna Pharmaceuticals Basic Information, Primary Hyperoxaluria Treatment

Manufacturing Base, Sales Area and Its Competitors

Table 85. Dicerna Pharmaceuticals Primary Hyperoxaluria Treatment Product Portfolios and Specifications

Table 86. Dicerna Pharmaceuticals Primary Hyperoxaluria Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 87. Dicerna Pharmaceuticals Main Business

Table 88. Dicerna Pharmaceuticals Latest Developments

Table 89. Allena Pharmaceuticals Basic Information, Primary Hyperoxaluria Treatment Manufacturing Base, Sales Area and Its Competitors

Table 90. Allena Pharmaceuticals Primary Hyperoxaluria Treatment Product Portfolios and Specifications

Table 91. Allena Pharmaceuticals Primary Hyperoxaluria Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 92. Allena Pharmaceuticals Main Business

Table 93. Allena Pharmaceuticals Latest Developments

Table 94. Biocodex Basic Information, Primary Hyperoxaluria Treatment Manufacturing Base, Sales Area and Its Competitors

Table 95. Biocodex Primary Hyperoxaluria Treatment Product Portfolios and Specifications

Table 96. Biocodex Primary Hyperoxaluria Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 97. Biocodex Main Business

Table 98. Biocodex Latest Developments

Table 99. Alnylam Pharmaceuticals Basic Information, Primary Hyperoxaluria Treatment Manufacturing Base, Sales Area and Its Competitors

Table 100. Alnylam Pharmaceuticals Primary Hyperoxaluria Treatment Product Portfolios and Specifications

Table 101. Alnylam Pharmaceuticals Primary Hyperoxaluria Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 102. Alnylam Pharmaceuticals Main Business

Table 103. Alnylam Pharmaceuticals Latest Developments

Table 104. Tecoland Corporation Basic Information, Primary Hyperoxaluria Treatment Manufacturing Base, Sales Area and Its Competitors

Table 105. Tecoland Corporation Primary Hyperoxaluria Treatment Product Portfolios and Specifications

Table 106. Tecoland Corporation Primary Hyperoxaluria Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 107. Tecoland Corporation Main Business

Table 108. Tecoland Corporation Latest Developments

Table 109. Zhejiang Tianxin Pharmaceutical Basic Information, Primary Hyperoxaluria Treatment Manufacturing Base, Sales Area and Its Competitors

Table 110. Zhejiang Tianxin Pharmaceutical Primary Hyperoxaluria Treatment Product Portfolios and Specifications

Table 111. Zhejiang Tianxin Pharmaceutical Primary Hyperoxaluria Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 112. Zhejiang Tianxin Pharmaceutical Main Business

Table 113. Zhejiang Tianxin Pharmaceutical Latest Developments

Table 114. Takeda Pharmaceuticals Basic Information, Primary Hyperoxaluria Treatment Manufacturing Base, Sales Area and Its Competitors

Table 115. Takeda Pharmaceuticals Primary Hyperoxaluria Treatment Product Portfolios and Specifications

Table 116. Takeda Pharmaceuticals Primary Hyperoxaluria Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 117. Takeda Pharmaceuticals Main Business

Table 118. Takeda Pharmaceuticals Latest Developments

Table 119. Wuxi Further Pharmaceutical Basic Information, Primary Hyperoxaluria Treatment Manufacturing Base, Sales Area and Its Competitors

Table 120. Wuxi Further Pharmaceutical Primary Hyperoxaluria Treatment Product Portfolios and Specifications

Table 121. Wuxi Further Pharmaceutical Primary Hyperoxaluria Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 122. Wuxi Further Pharmaceutical Main Business

Table 123. Wuxi Further Pharmaceutical Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Primary Hyperoxaluria Treatment
- Figure 2. Primary Hyperoxaluria Treatment Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Primary Hyperoxaluria Treatment Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Primary Hyperoxaluria Treatment Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Primary Hyperoxaluria Treatment Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Oral
- Figure 10. Product Picture of Intravenous
- Figure 11. Product Picture of Others
- Figure 12. Global Primary Hyperoxaluria Treatment Sales Market Share by Type in 2022
- Figure 13. Global Primary Hyperoxaluria Treatment Revenue Market Share by Type (2018-2023)
- Figure 14. Primary Hyperoxaluria Treatment Consumed in Type 1
- Figure 15. Global Primary Hyperoxaluria Treatment Market: Type 1 (2018-2023) & (K Units)
- Figure 16. Primary Hyperoxaluria Treatment Consumed in Type 2
- Figure 17. Global Primary Hyperoxaluria Treatment Market: Type 2 (2018-2023) & (K Units)
- Figure 18. Primary Hyperoxaluria Treatment Consumed in Type 3
- Figure 19. Global Primary Hyperoxaluria Treatment Market: Type 3 (2018-2023) & (K Units)
- Figure 20. Global Primary Hyperoxaluria Treatment Sales Market Share by Application (2022)
- Figure 21. Global Primary Hyperoxaluria Treatment Revenue Market Share by Application in 2022
- Figure 22. Primary Hyperoxaluria Treatment Sales Market by Company in 2022 (K Units)
- Figure 23. Global Primary Hyperoxaluria Treatment Sales Market Share by Company in 2022

Figure 24. Primary Hyperoxaluria Treatment Revenue Market by Company in 2022 (\$ Million)

Figure 25. Global Primary Hyperoxaluria Treatment Revenue Market Share by Company in 2022

Figure 26. Global Primary Hyperoxaluria Treatment Sales Market Share by Geographic Region (2018-2023)

Figure 27. Global Primary Hyperoxaluria Treatment Revenue Market Share by Geographic Region in 2022

Figure 28. Americas Primary Hyperoxaluria Treatment Sales 2018-2023 (K Units)

Figure 29. Americas Primary Hyperoxaluria Treatment Revenue 2018-2023 (\$ Millions)

Figure 30. APAC Primary Hyperoxaluria Treatment Sales 2018-2023 (K Units)

Figure 31. APAC Primary Hyperoxaluria Treatment Revenue 2018-2023 (\$ Millions)

Figure 32. Europe Primary Hyperoxaluria Treatment Sales 2018-2023 (K Units)

Figure 33. Europe Primary Hyperoxaluria Treatment Revenue 2018-2023 (\$ Millions)

Figure 34. Middle East & Africa Primary Hyperoxaluria Treatment Sales 2018-2023 (K Units)

Figure 35. Middle East & Africa Primary Hyperoxaluria Treatment Revenue 2018-2023 (\$ Millions)

Figure 36. Americas Primary Hyperoxaluria Treatment Sales Market Share by Country in 2022

Figure 37. Americas Primary Hyperoxaluria Treatment Revenue Market Share by Country in 2022

Figure 38. Americas Primary Hyperoxaluria Treatment Sales Market Share by Type (2018-2023)

Figure 39. Americas Primary Hyperoxaluria Treatment Sales Market Share by Application (2018-2023)

Figure 40. United States Primary Hyperoxaluria Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 41. Canada Primary Hyperoxaluria Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 42. Mexico Primary Hyperoxaluria Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 43. Brazil Primary Hyperoxaluria Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 44. APAC Primary Hyperoxaluria Treatment Sales Market Share by Region in 2022

Figure 45. APAC Primary Hyperoxaluria Treatment Revenue Market Share by Regions in 2022

Figure 46. APAC Primary Hyperoxaluria Treatment Sales Market Share by Type

(2018-2023)

Figure 47. APAC Primary Hyperoxaluria Treatment Sales Market Share by Application (2018-2023)

Figure 48. China Primary Hyperoxaluria Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 49. Japan Primary Hyperoxaluria Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 50. South Korea Primary Hyperoxaluria Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 51. Southeast Asia Primary Hyperoxaluria Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 52. India Primary Hyperoxaluria Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 53. Australia Primary Hyperoxaluria Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 54. China Taiwan Primary Hyperoxaluria Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 55. Europe Primary Hyperoxaluria Treatment Sales Market Share by Country in 2022

Figure 56. Europe Primary Hyperoxaluria Treatment Revenue Market Share by Country in 2022

Figure 57. Europe Primary Hyperoxaluria Treatment Sales Market Share by Type (2018-2023)

Figure 58. Europe Primary Hyperoxaluria Treatment Sales Market Share by Application (2018-2023)

Figure 59. Germany Primary Hyperoxaluria Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 60. France Primary Hyperoxaluria Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 61. UK Primary Hyperoxaluria Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 62. Italy Primary Hyperoxaluria Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 63. Russia Primary Hyperoxaluria Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 64. Middle East & Africa Primary Hyperoxaluria Treatment Sales Market Share by Country in 2022

Figure 65. Middle East & Africa Primary Hyperoxaluria Treatment Revenue Market Share by Country in 2022

Figure 66. Middle East & Africa Primary Hyperoxaluria Treatment Sales Market Share by Type (2018-2023)

Figure 67. Middle East & Africa Primary Hyperoxaluria Treatment Sales Market Share by Application (2018-2023)

Figure 68. Egypt Primary Hyperoxaluria Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 69. South Africa Primary Hyperoxaluria Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 70. Israel Primary Hyperoxaluria Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 71. Turkey Primary Hyperoxaluria Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 72. GCC Country Primary Hyperoxaluria Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 73. Manufacturing Cost Structure Analysis of Primary Hyperoxaluria Treatment in 2022

Figure 74. Manufacturing Process Analysis of Primary Hyperoxaluria Treatment

Figure 75. Industry Chain Structure of Primary Hyperoxaluria Treatment

Figure 76. Channels of Distribution

Figure 77. Global Primary Hyperoxaluria Treatment Sales Market Forecast by Region (2024-2029)

Figure 78. Global Primary Hyperoxaluria Treatment Revenue Market Share Forecast by Region (2024-2029)

Figure 79. Global Primary Hyperoxaluria Treatment Sales Market Share Forecast by Type (2024-2029)

Figure 80. Global Primary Hyperoxaluria Treatment Revenue Market Share Forecast by Type (2024-2029)

Figure 81. Global Primary Hyperoxaluria Treatment Sales Market Share Forecast by Application (2024-2029)

Figure 82. Global Primary Hyperoxaluria Treatment Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Primary Hyperoxaluria Treatment Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/G4CD728FDCB0EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G4CD728FDCB0EN.html>